Market Access, HEOR and Commercialization
- Market Forecasting & Competitive Intelligence
- Product Management & Lifecycle Strategy
- Pricing/reimbursement, HTA evidence packages, and payer negotiations
- PROs/HRQoL, value dossiers, and budget impact models
- Launch excellence, medical affairs & MSL strategies
- Patient advocacy partnerships and real-world uptake
- Evidence Synthesis & Network Meta-Analysis (NMA)
Even the most effective therapy has no impact until it reaches patients sustainably. Market Access, HEOR & Commercialization unites experts from pricing, health economics, medical affairs, and policy to align scientific value with payer and public expectations. This session explores the evidence-to-value continuum—how clinical data, real-world outcomes, and economic modeling converge to support reimbursement, formulary placement, and global launches. Participants will learn how to design evidence packages that balance regulatory, payer, and provider requirements and communicate differentiated value through transparent cost-effectiveness and budget-impact frameworks. The discussion covers both innovative launch strategies for novel therapies and lifecycle optimization for mature products.
Core topics include HTA readiness, global market dynamics, and evidence synthesis using meta-analysis and network models to fill comparative gaps. Attendees will gain insight into how patient-reported outcomes (PROs) and health-related quality-of-life (HRQoL) data contribute to value dossiers, as well as how real-world evidence supports label expansion, risk-sharing agreements, and outcomes-based contracts. For professionals seeking a Pharma Conference, the session provides frameworks for working effectively with payers, national agencies, and hospital systems. Equally important is the focus on health economics and outcomes research (HEOR) as a driver of patient-centered decision-making.
Case studies demonstrate how successful teams integrate commercial foresight early in clinical development, anticipating market segmentation, reference pricing, and affordability challenges. The session also covers pricing and reimbursement policies across the U.S., EU, and Asia-Pacific, analyzing how evolving value-assessment frameworks—ICER, NICE, and HTA 2.0—affect global strategy. Attendees will explore emerging tools like digital companion apps, real-world performance contracts, and data-driven launch excellence models that ensure long-term access and adoption.
Ready to Share Your Research?
Submit Your Abstract Here →Present your research under Market Access, HEOR and Commercialization
Value Generation and Access Excellence
Evidence Strategy & HTA Readiness
- Developing value dossiers that link endpoints to payer expectations.
- Using indirect treatment comparisons to complete the evidence package.
Pricing & Reimbursement Frameworks
- Balancing launch price with value perception and competitive references.
- Modeling affordability through risk-sharing and managed-entry agreements.
Real-World Evidence Integration
- Incorporating registries, EMRs, and claims data into HEOR models.
- Linking real-world performance with reimbursement renewals.
Patient-Reported Outcomes (PROs)
- Quantifying HRQoL and satisfaction to strengthen payer negotiations.
- Adapting questionnaires cross-culturally for global submissions.
Launch Planning & Market Shaping
- Pre-launch landscape mapping and stakeholder alignment.
- Post-launch analytics identifying uptake barriers and levers.
Commercial Governance
- Establishing cross-functional review between clinical, regulatory, and market access teams.
- Ensuring compliant communication of value claims globally.
Driving Real-World Impact
Value Evidence Integration
Bridges clinical outcomes and economics into actionable payer messages.
Early Commercial Insight
Informs trial design and endpoint selection for access success.
Sustainable Affordability
Develops pricing that balances innovation with accessibility.
Real-World Confidence
Uses registries and RWE to confirm effectiveness post-launch.
Cross-Functional Agility
Aligns development, medical, and commercial in shared KPIs.
Outcome-Based Partnerships
Implements contracts tying value to measurable health outcomes.
Global Access Expansion
Adapts strategy for emerging-market affordability frameworks.
Equitable Reach
Ensures therapies are accessible across economic and demographic lines.
Related Sessions You May Like
Join the Global Pharmaceutical Sciences Community
Connect with top researchers, industry experts, and innovators worldwide. Share your work and explore the latest advancements in drug discovery, translational research, and next-generation therapeutics.
